1 pleasing clients at a molecular and cellular level august 7, 2015

20
1 PLEASING CLIENTS AT A MOLECULAR AND CELLULAR LEVEL AUGUST 7, 2015

Upload: denis-marsh

Post on 06-Jan-2018

215 views

Category:

Documents


1 download

DESCRIPTION

3 TOPICS FOR DISCUSSION Pace of life sciences 1 Demands of the domain 2 Multi-faceted and interdisciplinary business of science 3 Focus on the customer: PDS in biotech 4 Industry challenges & beyond 5

TRANSCRIPT

Page 1: 1 PLEASING CLIENTS AT A MOLECULAR AND CELLULAR LEVEL AUGUST 7, 2015

1

PLEASING CLIENTS AT A MOLECULAR AND CELLULAR LEVEL

AUGUST 7, 2015

Page 2: 1 PLEASING CLIENTS AT A MOLECULAR AND CELLULAR LEVEL AUGUST 7, 2015

We live in a society exquisitely dependent on science and technology, in which hardly anyone knows anything about science and technology.

– Carl Sagan (1990)

Page 3: 1 PLEASING CLIENTS AT A MOLECULAR AND CELLULAR LEVEL AUGUST 7, 2015

3

TOPICS FOR DISCUSSION

Pace of life sciences1

Demands of the domain2

Multi-faceted and interdisciplinary business of science3

Focus on the customer: PDS in biotech4

Industry challenges & beyond5

Page 4: 1 PLEASING CLIENTS AT A MOLECULAR AND CELLULAR LEVEL AUGUST 7, 2015

4

SCIENCE DOMAIN: CHAOS & CHANGE

Science TechnologyHypotheses

ThroughputAnalyses

Conclusions

Ideas

Experiments

Data

Algorithms

MethodsAnd everyone is going through the process differently…

Models

Data Management

Page 5: 1 PLEASING CLIENTS AT A MOLECULAR AND CELLULAR LEVEL AUGUST 7, 2015

5

• Improvements in technology• Increase in amount of data• Development of algorithms

EVOLVING WITH THE PROCESS

Sample handling

Sample processing

Data storage

Data analysis

Page 6: 1 PLEASING CLIENTS AT A MOLECULAR AND CELLULAR LEVEL AUGUST 7, 2015

6

DURATION 10+ YEARS

TECHNOLOGY IS RACING FORWARD, BUT DRUG DEVELOPMENT CYCLE IS LONG

LEAD IDENTIFICATION

PRE-CLINICAL CLINICAL TRIALS

PHASE I PHASE II PHASE III

FDA REVIEW

3-6 YRS 6-7 YRS 1-2 YRS

MANY COMPOUNDS

250 COMPOUNDS

20-100 VOLUNTEERS

100-500 VOLUNTEERS

1,000-5,000 VOLUNTEERS

ONE APPROVED

DRUG

? YRS

TARGET ID &

VALIDATION

Genomics ProteomicsTranscriptomics Epigenomics

ChemistryMetabolomicsToxicity

And all that data has to be “handled”!

Page 7: 1 PLEASING CLIENTS AT A MOLECULAR AND CELLULAR LEVEL AUGUST 7, 2015

7

DURATION >10 YEARS

TECHNOLOGY IS RACING FORWARD, BUT CYCLE OF DRUG DEVELOPMENT IS LONG

LEAD IDENTIFICATION

PRE-CLINICAL CLINICAL TRIALS

PHASE I PHASE II PHASE III

FDA REVIEW

3-6 YRS 6-7 YRS 1-2 YRS

MANY COMPOUNDS

250 COMPOUNDS

20-100 VOLUNTEERS

100-500 VOLUNTEERS

1,000-5,000 VOLUNTEERS

ONE APPROVED

DRUG

? YRS

TARGET ID &

VALIDATION

Genomics ProteomicsTranscriptomics Epigenomics

ChemistryMetabolomicsToxicity

LEAD IDENTIFICATION

PRE-CLINICAL

3-6 YRS

MANY COMPOUNDS

250 COMPOUNDS

? YRS

TARGET ID &

VALIDATION

The greatest improvement to this cycle’s efficiency can be achieved

before the clinical phase

Page 8: 1 PLEASING CLIENTS AT A MOLECULAR AND CELLULAR LEVEL AUGUST 7, 2015

8

THE LIFE SCIENCES MILIEU

ChemistryEngineering

Regulatory

ClinicalAnimal Sciences

Biology

Informatics

FinanceOperations

IT

Legal

Page 9: 1 PLEASING CLIENTS AT A MOLECULAR AND CELLULAR LEVEL AUGUST 7, 2015

9

• Scientists and their habits• Reconciling business & science• Need someone to:

• Keep everyone focused• Suggest methods• Make workflows easy• Do it fast!

FROM SPREADSHEETS TO SYSTEMS: GETTING USERS ONBOARD

Page 10: 1 PLEASING CLIENTS AT A MOLECULAR AND CELLULAR LEVEL AUGUST 7, 2015

10

FOCUS ON THE CUSTOMER: DELIVERING ON THE PROMISE OF PDS

DirectionIdentify direction of the business

ScienceNovel technologies speed up the science

TechnologiesBring novel technologies to the business

BusinessScience drives business forward

Page 11: 1 PLEASING CLIENTS AT A MOLECULAR AND CELLULAR LEVEL AUGUST 7, 2015

11

SYSTEM TO ACCELERATE & OPTIMIZE DRUG DESIGN

https://www.youtube.com/watch?v=HjB536Glvpw

Page 12: 1 PLEASING CLIENTS AT A MOLECULAR AND CELLULAR LEVEL AUGUST 7, 2015

12

• Covers the process

• Open for integration

• With scientific context

• Allows integrated questions to be posed

A PRODUCT: DRUG DESIGN STUDIO

Page 13: 1 PLEASING CLIENTS AT A MOLECULAR AND CELLULAR LEVEL AUGUST 7, 2015

13

SYSTEM TO ACCELERATE & OPTIMIZE DRUG DESIGN

https://www.youtube.com/watch?v=vR3nauEkiuI

Page 14: 1 PLEASING CLIENTS AT A MOLECULAR AND CELLULAR LEVEL AUGUST 7, 2015

14

For specific business need

To be used across disciplines

With best scientific practices

AT THE END OF THE DAY: PRODUCT BUILT

1

2

3

We have software that captures & searches data.The Question is “What’s next?”

Page 15: 1 PLEASING CLIENTS AT A MOLECULAR AND CELLULAR LEVEL AUGUST 7, 2015

15

ONE STEP BEYOND

http://telemedicina.med.muni.cz/

Page 16: 1 PLEASING CLIENTS AT A MOLECULAR AND CELLULAR LEVEL AUGUST 7, 2015

16

SOLUTIONS FOR THE BIOTECH BUSINESS

CLIENTWhat do I do with the petabytes of

chemistry, biology, modeling, in-vivo, clinical data?

Provide system for data tracking & integration

How do I search it?Develop search algorithms that allow

omni-directional information flow across disciplines

What can I do with it? Develop analysis algorithms and visualization tools

EPAM

Page 17: 1 PLEASING CLIENTS AT A MOLECULAR AND CELLULAR LEVEL AUGUST 7, 2015

17

EXAMPLE: ELECTRONIC NOTEBOOK

• GOOD:

• Searchable• Achievable

• BAD:

• Organization• Data extraction • Visualization

• Need: Different notebooks for different disciplines (modular) with common back end and visualization layer

Biologists

Chemists

Informaticists

Clinicians

Animal Scientists

Page 18: 1 PLEASING CLIENTS AT A MOLECULAR AND CELLULAR LEVEL AUGUST 7, 2015

18

Onsite team must speak client’s language

TO ACHIEVE SUCCESS WITH CUSTOMER, REMEMBER:

Business Technology

Science

EPAM Team

Page 19: 1 PLEASING CLIENTS AT A MOLECULAR AND CELLULAR LEVEL AUGUST 7, 2015

19

THANKS TO

Thank You!

Page 20: 1 PLEASING CLIENTS AT A MOLECULAR AND CELLULAR LEVEL AUGUST 7, 2015

20